


PDE1-IN-2

Cat. No.:	HY-101490		
CAS No.:	1904611-63-7		
Molecular Formula:	C ₁₆ H ₂₁ BrN ₄ O ₂		
Molecular Weight:	381.27		
Target:	Phosphodiesterase (PDE)		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 25 mg/mL (65.57 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.6228 mL	13.1141 mL	26.2281 mL
		5 mM	0.5246 mL	2.6228 mL	5.2456 mL
		10 mM	0.2623 mL	1.3114 mL	2.6228 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (6.56 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	PDE1-IN-2 is a PDE1 inhibitor extracted from patent WO2016/55618 A1, example 31. PDE1-IN-2 has IC ₅₀ values of 6 nM, 140 nM and 164 nM for PDE1C, PDE1B and PDE1A, respectively. PDE1-IN-2 is developed for the research of neurodegenerative disorders and psychiatric disorders ^[1] .		
IC ₅₀ & Target	PDE1A 164 nM (IC ₅₀)	PDE1B 140 nM (IC ₅₀)	PDE1C 6 nM (IC ₅₀)
In Vitro	PDE1 enzymes are expressed in the central nervous system (CNS), making this gene family an attractive source of new targets for the treatment of psychiatric and neurodegenerative disorders ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		

REFERENCES

[1]. Jan Kehler, et al. Triazolopyrazinones as pde1 inhibitors. WO2016055618A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA